Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these results and what they could mean for investors.
Danish weight-loss drugmaker Novo Nordisk posts huge profit jump
Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 percent in 2024 to 100 billion Danish kroner ($13.
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is hunting for new patients to maintain its crown as Europe’s most valuable company.
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.
Why Novo Nordisk surged 14% on new weight-loss drug results
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce competition in the weight-loss market.
Novo Nordisk beats in Q4 as Wegovy sales more than double
Novo Nordisk (NVO) stock and Eli Lilly (LLY) stock higher as Novo (NVO) reports strong Q4 2024 earnings, driven by sales growth in its GLP-1 drugs. Read more here.
Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.
Novo Nordisk’s Wegovy Drug Sales Miss Expectations
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year.
Bloomberg L.P.12d
Novo Shares Soar as Experimental Shot Shows 22% Weight Loss
Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s ...
BioSpace1d
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...